Kazemi, F., Liu, J., Parker, M., Jimenez, A. E., Ahmed, A. K., Salvatori, R., Hamrahian, A. H., Rowan, N. R., Ramanathan, M., London, N. R., Ishii, M., Rincon-Torroella, J., Gallia, G. L., & Mukherjee, D. (2025). Hospital frailty risk score predicts postoperative outcomes after endoscopic endonasal resection of non-functioning pituitary adenomas. Pituitary, 28(1). https://doi.org/10.1007/s11102-024-01496-8

Giustina, A., Uygur, M. M., Frara, S., Barkan, A., Biermasz, N. R., Chanson, P., Freda, P., Gadelha, M., Haberbosch, L., Kaiser, U. B., Lamberts, S., Laws, E., Nachtigall, L. B., Popovic, V., Schilbach, K., Lely, A. J. van der, Wass, J. A. H., Melmed, S., & Casanueva, F. F. (2025). Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs). Pituitary, 28(1). https://doi.org/10.1007/s11102-024-01485-x

Giustina, A., Uygur, M. M., Frara, S., Barkan, A., Biermasz, N. R., Chanson, P., Freda, P., Gadelha, M., Haberbosch, L., Kaiser, U. B., Lamberts, S., Laws, E., Nachtigall, L. B., Popovic, V., Reincke, M., van der Lely, A. J., Wass, J. A. H., Melmed, S., & Casanueva, F. F. (2024). Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary, 27(4), 381–388. https://doi.org/10.1007/s11102-024-01397-w

Prince, E. W., Apps, J. R., Jeang, J., Chee, K., Medlin, S., Jackson, E. M., Dudley, R., Limbrick, D., Naftel, R., Johnston, J., Feldstein, N., Prolo, L. M., Ginn, K., Niazi, T., Smith, A., Kilburn, L., Chern, J., Leonard, J., Lam, S., … Hankinson, T. C. (2024). Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis. Neuro-Oncology, 26(6), 1109–1123. https://doi.org/10.1093/neuonc/noae015

Lin, A. L., Rudneva, V. A., Richards, A. L., Zhang, Y., Woo, H. J., Cohen, M., Tisnado, J., Majd, N., Wardlaw, S. L., Page-Wilson, G., Sengupta, S., Chow, F., Goichot, B., Ozer, B. H., Dietrich, J., Nachtigall, L., Desai, A., Alano, T., Ogilive, S., … Tabar, V. (2024). Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02736-8

Heneghan, L. J., Tsang, A., Dimino, C., Khandji, A. G., Panigrahi, S. K., & Page-Wilson, G. (2023). Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. The Journal of Clinical Endocrinology & Metabolism, 109(2), e667–e674. https://doi.org/10.1210/clinem/dgad545

Jimenez, A. E., Azad, T. D., & Mukherjee, D. (2023). Decreasing Reimbursement of Pituitary Tumor Surgery: An Analysis of Medicare Data From 2010 to 2020. Neurosurgery, 94(1), 140–146. https://doi.org/10.1227/neu.0000000000002636

Giustina, A., Uygur, M. M., Frara, S., Barkan, A., Biermasz, N. R., Chanson, P., Freda, P., Gadelha, M., Kaiser, U. B., Lamberts, S., Laws, E., Nachtigall, L. B., Popovic, V., Reincke, M., Strasburger, C., van der Lely, A. J., Wass, J. A. H., Melmed, S., & Casanueva, F. F. (2023). Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary, 26(5), 583–596. https://doi.org/10.1007/s11102-023-01345-0

Lin, A. L., Geer, E. B., Lala, N., Page-Wilson, G., Magge, R., Young, R. J., & Tabar, V. (2023). The treatment of aggressive prolactinomas with everolimus. Pituitary, 26(4), 474–481. https://doi.org/10.1007/s11102-023-01340-5

Wexler, T. L., & Page‐Wilson, G. (2023). Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies. British Journal of Clinical Pharmacology, 89(4), 1304–1317. Portico. https://doi.org/10.1111/bcp.15660